These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 28863455)
21. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma. Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803 [TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Panwalkar P; Clark J; Ramaswamy V; Hawes D; Yang F; Dunham C; Yip S; Hukin J; Sun Y; Schipper MJ; Chavez L; Margol A; Pekmezci M; Chung C; Banda A; Bayliss JM; Curry SJ; Santi M; Rodriguez FJ; Snuderl M; Karajannis MA; Saratsis AM; Horbinski CM; Carret AS; Wilson B; Johnston D; Lafay-Cousin L; Zelcer S; Eisenstat D; Silva M; Scheinemann K; Jabado N; McNeely PD; Kool M; Pfister SM; Taylor MD; Hawkins C; Korshunov A; Judkins AR; Venneti S Acta Neuropathol; 2017 Nov; 134(5):705-714. PubMed ID: 28733933 [TBL] [Abstract][Full Text] [Related]
23. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548 [TBL] [Abstract][Full Text] [Related]
24. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Kilday JP; Mitra B; Domerg C; Ward J; Andreiuolo F; Osteso-Ibanez T; Mauguen A; Varlet P; Le Deley MC; Lowe J; Ellison DW; Gilbertson RJ; Coyle B; Grill J; Grundy RG Clin Cancer Res; 2012 Apr; 18(7):2001-11. PubMed ID: 22338015 [TBL] [Abstract][Full Text] [Related]
25. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma. Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862 [TBL] [Abstract][Full Text] [Related]
26. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Mack SC; Pajtler KW; Chavez L; Okonechnikov K; Bertrand KC; Wang X; Erkek S; Federation A; Song A; Lee C; Wang X; McDonald L; Morrow JJ; Saiakhova A; Sin-Chan P; Wu Q; Michaelraj KA; Miller TE; Hubert CG; Ryzhova M; Garzia L; Donovan L; Dombrowski S; Factor DC; Luu B; Valentim CLL; Gimple RC; Morton A; Kim L; Prager BC; Lee JJY; Wu X; Zuccaro J; Thompson Y; Holgado BL; Reimand J; Ke SQ; Tropper A; Lai S; Vijayarajah S; Doan S; Mahadev V; Miñan AF; Gröbner SN; Lienhard M; Zapatka M; Huang Z; Aldape KD; Carcaboso AM; Houghton PJ; Keir ST; Milde T; Witt H; Li Y; Li CJ; Bian XW; Jones DTW; Scott I; Singh SK; Huang A; Dirks PB; Bouffet E; Bradner JE; Ramaswamy V; Jabado N; Rutka JT; Northcott PA; Lupien M; Lichter P; Korshunov A; Scacheri PC; Pfister SM; Kool M; Taylor MD; Rich JN Nature; 2018 Jan; 553(7686):101-105. PubMed ID: 29258295 [TBL] [Abstract][Full Text] [Related]
27. MYCN amplification drives an aggressive form of spinal ependymoma. Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211 [TBL] [Abstract][Full Text] [Related]
28. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Reardon DA; Entrekin RE; Sublett J; Ragsdale S; Li H; Boyett J; Kepner JL; Look AT Genes Chromosomes Cancer; 1999 Mar; 24(3):230-7. PubMed ID: 10451703 [TBL] [Abstract][Full Text] [Related]
29. Uncommon pediatric tumors of the posterior fossa: pathologic and molecular features. Dunham C Childs Nerv Syst; 2015 Oct; 31(10):1729-37. PubMed ID: 26351226 [TBL] [Abstract][Full Text] [Related]
30. Radiology Profile as a Potential Instrument to Differentiate Between Posterior Fossa Ependymoma (PF-EPN) Group A and B. Yonezawa U; Karlowee V; Amatya VJ; Takayasu T; Takano M; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F World Neurosurg; 2020 Aug; 140():e320-e327. PubMed ID: 32428725 [TBL] [Abstract][Full Text] [Related]
31. Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma. Rand V; Prebble E; Ridley L; Howard M; Wei W; Brundler MA; Fee BE; Riggins GJ; Coyle B; Grundy RG; Br J Cancer; 2008 Oct; 99(7):1136-43. PubMed ID: 18781180 [TBL] [Abstract][Full Text] [Related]
32. Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology. Gödicke S; Kresbach C; Ehlert M; Obrecht D; Altendorf L; Hack K; von Hoff K; Carén H; Melcher V; Kerl K; Englinger B; Filbin M; Pajtler KW; Gojo J; Pietsch T; Rutkowski S; Schüller U Acta Neuropathol; 2024 Jan; 147(1):23. PubMed ID: 38265527 [TBL] [Abstract][Full Text] [Related]
33. Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Donson AM; Amani V; Warner EA; Griesinger AM; Witt DA; Levy JMM; Hoffman LM; Hankinson TC; Handler MH; Vibhakar R; Dorris K; Foreman NK Mol Cancer Ther; 2018 Sep; 17(9):1984-1994. PubMed ID: 29925527 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Ramaswamy V; Hielscher T; Mack SC; Lassaletta A; Lin T; Pajtler KW; Jones DT; Luu B; Cavalli FM; Aldape K; Remke M; Mynarek M; Rutkowski S; Gururangan S; McLendon RE; Lipp ES; Dunham C; Hukin J; Eisenstat DD; Fulton D; van Landeghem FK; Santi M; van Veelen ML; Van Meir EG; Osuka S; Fan X; Muraszko KM; Tirapelli DP; Oba-Shinjo SM; Marie SK; Carlotti CG; Lee JY; Rao AA; Giannini C; Faria CC; Nunes S; Mora J; Hamilton RL; Hauser P; Jabado N; Petrecca K; Jung S; Massimi L; Zollo M; Cinalli G; Bognár L; Klekner A; Hortobágyi T; Leary S; Ermoian RP; Olson JM; Leonard JR; Gardner C; Grajkowska WA; Chambless LB; Cain J; Eberhart CG; Ahsan S; Massimino M; Giangaspero F; Buttarelli FR; Packer RJ; Emery L; Yong WH; Soto H; Liau LM; Everson R; Grossbach A; Shalaby T; Grotzer M; Karajannis MA; Zagzag D; Wheeler H; von Hoff K; Alonso MM; Tuñon T; Schüller U; Zitterbart K; Sterba J; Chan JA; Guzman M; Elbabaa SK; Colman H; Dhall G; Fisher PG; Fouladi M; Gajjar A; Goldman S; Hwang E; Kool M; Ladha H; Vera-Bolanos E; Wani K; Lieberman F; Mikkelsen T; Omuro AM; Pollack IF; Prados M; Robins HI; Soffietti R; Wu J; Metellus P; Tabori U; Bartels U; Bouffet E; Hawkins CE; Rutka JT; Dirks P; Pfister SM; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Ellison DW; Taylor MD J Clin Oncol; 2016 Jul; 34(21):2468-77. PubMed ID: 27269943 [TBL] [Abstract][Full Text] [Related]
35. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome. Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114 [TBL] [Abstract][Full Text] [Related]
36. Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis. Wang G; Jia Y; Ye Y; Kang E; Chen H; Wang J; He X J Transl Med; 2021 Apr; 19(1):174. PubMed ID: 33902636 [TBL] [Abstract][Full Text] [Related]
37. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review. Nobusawa S; Hirato J; Yokoo H Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241 [TBL] [Abstract][Full Text] [Related]
38. Real-time quantitative PCR analysis of pediatric ependymomas identifies novel candidate genes including TPR at 1q25 and CHIBBY at 22q12-q13. Karakoula K; Suarez-Merino B; Ward S; Phipps KP; Harkness W; Hayward R; Thompson D; Jacques TS; Harding B; Beck J; Thomas DG; Warr TJ Genes Chromosomes Cancer; 2008 Nov; 47(11):1005-22. PubMed ID: 18663750 [TBL] [Abstract][Full Text] [Related]